PRESS RELEASE published on 09/06/2024 at 17:45, 2 years ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 2 years ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 2 years ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 2 years ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 2 years 2 months ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 2 years 2 months ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
BRIEF published on 06/07/2024 at 17:50, 2 years 3 months ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
PRESS RELEASE published on 06/07/2024 at 17:45, 2 years 3 months ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
BRIEF published on 05/29/2024 at 17:50, 2 years 3 months ago Median Technologies to Attend 2024 ASCO Annual Meeting in Chicago Clinical Trials Oncology Imaging Solutions Median Technologies ASCO Annual Meeting
PRESS RELEASE published on 05/29/2024 at 17:45, 2 years 3 months ago Inside Information / Other news releases Median Technologies to participate in the 2024 ASCO Annual Meeting at McCormick Place, Chicago, IL, USA. Abstract on double reading performance in lung clinical trials. Event details and company overview Clinical Trials Oncology Medical Imaging Median Technologies ASCO Annual Meeting
Published on 09/19/2026 at 00:55, 1 day 13 hours ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 1 day 16 hours ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 17 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 23 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/20/2026 at 09:05, 5 hours 10 minutes ago Huawei Digital Power Showcases Multi-Scenario Solutions Featuring Grid Forming and AI at IDEE 2026
Published on 09/20/2026 at 06:30, 7 hours 45 minutes ago Huawei Grid-Interactive AIDC Solution: Shaping the New Paradigm of AI Infrastructure
Published on 09/20/2026 at 04:35, 9 hours 40 minutes ago How to Achieve Sustainable Power Without Changing Your Existing Backup System
Published on 09/19/2026 at 16:40, 21 hours 35 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 1 day 1 hour ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/18/2026 at 18:34, 1 day 19 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 2 days 20 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
